Abstract: A pharmaceutical composition for oral consumption in liquid form is provided, characterized in that the composition contains a drug, preferably a lipophilic NSAID, complexed to .beta.-cyclodextrin in a formulation also containing an acid-base couple, preferably an effervescent acid-base couple. The weight of the acid-base couple is greater than 1% of the weight of water in which the composition is to be dissolved, and provides an acid or neutral pH.
Abstract: A method for the treatment of PHN in mammals, including humans, which method comprises administering an effective amount of a compound of formula (A), or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
June 20, 1996
Date of Patent:
February 2, 1999
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Ronald James Boon, David Ronald John Griffin
Abstract: The present invention discloses tablet formulations, produced by dry roller compaction comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant. The granulates are compacted together into a tablet with an extra-granular disintegrant, an optional extragranular lubricant and excipients.
Type:
Grant
Filed:
October 8, 1996
Date of Patent:
January 19, 1999
Assignee:
Laboratorios Beecham SA
Inventors:
Luis Carvajal Martin, Juan Dedios Romero
Abstract: The present invention discloses tablet formulations, produced by dry roller compaction comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant. The granulates are compacted together into a tablet with an extra-granular disintegrant, an optional extragranular lubricant and excipients.
Type:
Grant
Filed:
October 9, 1996
Date of Patent:
December 22, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Luis Carvajal Martin, Juan Dedios Romero
Abstract: A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
Type:
Grant
Filed:
September 1, 1995
Date of Patent:
November 24, 1998
Assignee:
SmithKline Beecham plc
Inventors:
Hugh John Field, Alana Maureen Thackray, Teresa Helen Bacon, David Sutton, Richard Anthony Vere Hodge
Abstract: A pharmaceutical granular composition and method for taste masking bitter, or unpleasant tasting drugs comprising a drug core of a nonsteriodal anti-inflammatory drug, and as a taste masking agents, methacrylate ester copolymers. The method comprises coating the drug cores with separate layers of aqueous dispersions of the copolymers. Additionally, the coating composition may contain plasticizers and conventional excipients. The granules of the present invention can be used in the preparation of chewable tablets which have good palatability and bioavailability. Preferable copolymers are poly(ethylacrylate, methylmethacrylate) to which quaternary ammonium groups have been introduced to modify the permeability of the ester. The coating system of this invention releases the drug by diffusion and is influenced by drug solubility and media pH.
Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of chronic inflammatory disease states.
Abstract: A pharmaceutical formulation comprising an amoxycillin hydrate and an effervescent couple, for example citric acid plus sodium bicarbonate or sodium glycine carbonate, or tartaric acid or malic acid plus sodium carbonate. Potassium equivalents of these sodium salts may be used. The formulations may be free flowing powders or granules, or tablets.
Type:
Grant
Filed:
October 24, 1994
Date of Patent:
September 29, 1998
Assignee:
Beecham Group plc
Inventors:
David Roy Merrifield, Paul Laurence Carter, David George Doughty
Abstract: Solid phase combinatorial synthesis is carried out in a multi-reactor synthesizer comprising an array of separate reactor cells containing a solid reaction support medium. Subsets of reactor cells are interconnected with one another in a desired pattern, and, in a first reaction step, reagents are circulated through the subsets. After the first reaction step is completed, the reactor cells are rearranged into a new configuration of subsets, and the same, or other, reagents are circulated through the new subsets. The process can be repeated to produce large numbers of compounds differing from one another.
Abstract: This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease scates mediated by the chemokine, Interleukin-8 (IL-8). In particular, this invention relates to the novel compounds of Formula (Ia) and their use in treating chemokine mediated diseases wherein the chemokine binds to an IL-8 a or b receptor. Compounds of Formula (Ia) are represented by the structure: ##STR1## wherein interalia, X is oxygen or sulfur;Rb is NR.sub.6 R.sub.7, alkcyl, aryl, arylC.sub.1-4 alkyl, aryl C.sub.2-4 alkenyl, heteroaryl, heteroarylC.sub.1-4 alkyl, heteroarylC.sub.2-4 alkenyl, heterocyclic or heterocyclic C.sub.1-4 alkyl, or a heterocyclic C.sub.2-4 alkenyl moiety, camphor, all of which may be optionally substituted;R.sub.1 is independently selected from hydrogen; halogen; nitro; cyano; C.sub.1-10 alkyl; halosubstituted C.sub.1-10 alkyl; C.sub.2-10 alkoxy; halosubstituted C.sub.1-10 alkoxy; azide; (CR.sub.8 R.sub.8)q S(O).sub.t R.sub.4 ; hydroxy; hydroxy substituted C.sub.
Type:
Grant
Filed:
August 21, 1996
Date of Patent:
July 14, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Katherine Louisa Widdowson, Daniel Frank Veber, Anthony Joseph Jurewicz, Robert Philip Hertzberg, Melvin Clarence Rutledge, Jr.
Abstract: The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction.
Abstract: A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): ##STR1## or if appropriate a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 each independently represent alkyl or a moiety of formula (a):--(CH.sub.2).sub.m --A (a)whereinm represents zero or an integer 1, 2 or 3;A represents a substituted or unsubstituted cyclic hydrocarbon radical; andR.sup.3 represents a halogen atom, a nitro group, or a group --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 each independently represents hydrogen, alkyl or alkylcarbonyl or R.sup.4 and R.sup.5 together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
March 31, 1998
Assignee:
Beecham Group
Inventors:
Barbara Ann Spicer, Harry Smith, Harald Maschler